Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Assets (2021 - 2025)

Quantum Biopharma's Assets history spans 5 years, with the latest figure at $11.2 million for Q4 2025.

  • On a quarterly basis, Assets fell 34.8% to $11.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.2 million, a 34.8% decrease, with the full-year FY2025 number at $11.2 million, down 34.8% from a year prior.
  • Assets hit $11.2 million in Q4 2025 for Quantum Biopharma, down from $14.2 million in the prior quarter.
  • Over the last five years, Assets for QNTM hit a ceiling of $63.0 million in Q4 2021 and a floor of $11.2 million in Q4 2025.
  • Historically, Assets has averaged $22.6 million across 5 years, with a median of $16.2 million in 2024.
  • Biggest five-year swings in Assets: plummeted 54.51% in 2023 and later grew 0.33% in 2025.
  • Tracing QNTM's Assets over 5 years: stood at $63.0 million in 2021, then crashed by 38.99% to $38.4 million in 2022, then plummeted by 54.51% to $17.5 million in 2023, then dropped by 2.03% to $17.1 million in 2024, then plummeted by 34.8% to $11.2 million in 2025.
  • Business Quant data shows Assets for QNTM at $11.2 million in Q4 2025, $14.2 million in Q3 2025, and $15.3 million in Q2 2025.